Predictors of adverse events after the administration of acellular and whole-cell diphtheria-tetanus-pertussis vaccines

Vaccine

Volumn 16, Issue 2-3, 1998, Pages 320-322

  Tozzi, Alberto Eugenio ^a   Degli Atti, Marta Luisa Ciofi ^a   Wassilak, Steven Gary Fite ^b   Salmaso, Stefania ^a   Panei, Pietro ^a   Anemona, Alessandra ^a   Luzi, Stefania ^a   Greco, Donato ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Acellular vaccine; DT; Pertussis; Safety; Whole cell vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEVER; HUMAN; IMMUNOGENICITY; INJECTION SITE; INTRAMUSCULAR DRUG ADMINISTRATION; IRRITABILITY; MAJOR CLINICAL STUDY; PERTUSSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

DIPHTHERIA; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOUBLE-BLIND METHOD; FEMALE; FEVER; HUMANS; INFANT; MALE; RISK FACTORS; TETANUS; WHOOPING COUGH;

EID: 0031986151     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00163-1     Document Type: Article

References (12)

1. 1 Ad Hoc Group for the Study of Pertussis Vaccines, Placebo-controlled trial of two acellular pertussis vaccines in Sweden - protective efficacy and adverse events. Lancet, 1988, 1, 955-960.
2. 2 Heininger, U., Cherry, J. D. and Christenson, P. D. et al. Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany. Vaccine 1994, 12, 81-86.
3. 3 Decker, M.D., Edwards, K.M. and Steinhoff, M.C. et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995, 96, 557-566.
4. 4 Greco, D., Salmaso, S. and Mastrantonio, P. et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. New England Journal of Medicine 1996, 334, 341-348.
5. 5 Gustafsson, L., Hallander, H.O., Olin, P., Reizenstein, E. and Storsaeter, J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. New England Journal of Medicine 1996, 334, 349-355.
6. 6 Pichichero, M.E., Christy, C. and Decker, M.D. et al. Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics 1995, 96, 588-592.
7. 7 Trollfors, B., Taranger, J. and Lagergard, T. ef al. A placebo-controlled trial of a pertussis-toxoid vaccine. New England Journal of Medicine 1995, 333, 1045-1050.
8. 8 Schmitt, H.-J., Wirsing von Konig, C.-H. and Neiss, A. et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996, 275, 37-41.
9. 9 Baraff, L.J., Cody, C.L. and Cherry, J.D. DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions, and dose. Pediatrics 1984, 73, 31-36.
10. 10 Ipp, M.M., Gold, R., Goldbach, M., Maresky, D.C., Saunders, N., Greenberg, S. and Davy, T. Adverse reactions to diphtheria, tetanus, pertussis-polio vaccination at 18 months of age: effect of injection site and needle length. Pediatrics 1989, 83, 679-682.
11. 11 Bergeson, P.S., Singer, S.A. and Kaplan, A.M. Intramuscular injections in children. Pediatrics 1982, 70, 944-948.
12. 12 Salmaso, S., Mastrantonio, P., Giuliano, M. et al., Efficacy trial of an acellular pertussis vaccine in Italy. Final report Stage I, 27/7/1995.